HOUSTON, Nov. 9, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the
"Company"), a biopharmaceutical company specializing in the
development of novel treatments for primary and metastatic cancers
of the brain and central nervous system, today announced it will be
issuing a video update on November
12th, 2020 at 4:30pm
ET to discuss the clinical trial design for its upcoming
Phase 2 U.S. trial for Berubicin, its lead drug candidate for the
treatment of glioblastoma multiforme (GBM), an aggressive form of
brain cancer, currently considered incurable. The discussion will
be moderated by Robert LeBoyer,
Managing Director of Equity Research at Ladenburg Thalmann &
Co., Inc.
The Company plans to submit an Investigational New Drug (IND)
application to the U.S. Food & Drug Administration (FDA), which
includes a novel clinical trial designed to build on the
encouraging results observed in a prior Phase 1. The Phase 2 trial
will randomize patients to Berubicin or standard of care. This
upcoming trial will include interim assessments that will evaluate
the comparative safety and effectiveness of these treatments with
an adaptive design intended to complete a thorough investigation
into Berubicin as expeditiously as possible.
Details of the webinar are below:
Date: November
12th, 2020
Time: 4:30 PM ET
Link: https://cnspharma.com/webcast-november-2020/
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary and
metastatic cancers of the brain and central nervous system. Its
lead drug candidate, Berubicin, is proposed for the treatment of
glioblastoma multiforme (GBM), an aggressive and incurable form of
brain cancer. CNS holds a worldwide exclusive license to the
Berubicin chemical compound and has acquired all data and know-how
from Reata Pharmaceuticals, Inc. related to a completed Phase 1
clinical trial with Berubicin in malignant brain tumors, which
Reata conducted in 2006. In this trial the overall response rate of
stable disease or better was 44%. This 44% disease control rate was
based on 11 patients (out of 25 evaluable patients) with stable
disease, plus responders. One patient experienced a durable
complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a
limited patient sample size and, while promising, are not a
guarantee that similar results will be achieved in subsequent
trials. By the end of 2020, CNS expects to commence a Phase 2
clinical trial of Berubicin for the treatment of GBM in the U.S.,
while a sub-licensee partner undertakes a Phase 2 trial in adults
and a first-ever Phase 1 trial in pediatric GBM patients in
Poland. Its second drug candidate,
WP1244, is a novel DNA binding agent that has shown in preclinical
studies that it is 500 times more potent than the chemotherapeutic
agent daunorubicin in inhibiting tumor cell proliferation.
For more information, please visit www.CNSPharma.com.
Forward-Looking Statements
Some of the statements in
this press release are forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of the Company to seek
accelerated approval from the FDA of a New Drug Application (NDA)
following the planned Berubicin trial. These statements relate to
future events, future expectations, plans and prospects. Although
CNS believes the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. CNS has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks, uncertainties
and other factors, including those discussed under Item 1A. "Risk
Factors" in CNS's most recently filed Form 10-K filed with the
Securities and Exchange Commission ("SEC") and updated from time to
time in its Form 10-Q filings and in its other public filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of its date. CNS undertakes no obligation to
update any forward-looking statements contained in this press
release to reflect events or circumstances occurring after its date
or to reflect the occurrence of unanticipated events.
CONTACTS:
Investor Relations Contact
James Salierno
The Ruth Group
646-536-7028
jsalierno@theruthgroup.com
Media Contact
Kirsten
Thomas
The Ruth Group
(508) 280-6592
kthomas@theruthgroup.com
Corporate Communications:
InvestorBrandNetwork
(IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-adaptive-trial-design-for-berubicin-phase-2-clinical-trial-to-be-submitted-for-fda-review-301168491.html
SOURCE CNS Pharmaceuticals, Inc.